Newron to present data and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP) The importance of glutamate release modulation by evenamide used as an add-on therapy for patients with schizophrenia inadequately responding to their second-generati [ … ]

Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)  ENIGMA-TRS 1 is an international, one-year, double-blind, placebo-controlled Phase III study in at least 600 patients; 12-week study results expected in Q4 2026 Evenamide, a first-in-class glu [ … ]

Newron notes the publication of new preclinical research suggesting evenamide ameliorates schizophrenia-related dysfunction New findings published in Neuropsychopharmacology are the first to demonstrate that evenamide targets the key site of schizophrenia pathology in the hippocampus, and so could be an ideal therapeutic agent for treatment of the [ … ]

Newron announces approval for pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)  ENIGMA-TRS 1 is an international, one-year, double-blind, placebo-controlled Phase III study in at least 600 patients; enrollment to start imminently; 12-week study results expected in Q4 202 [ … ]

Newron presents 2024 financial results and provides 2025 outlook Milan, Italy, April 1, 2025, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financ [ … ]

Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent Chairman  Expected to succeed Dr. Ulrich Köstlin who has notified Newron of his intention to retire after 12 years of service as Chairman of its Board of Directors, effective following completion of this year’s AGM  Chris Martin, forme [ … ]

 Newron and Myung In Pharm announce license agreementfor evenamide in South Korea Myung In Pharm to develop, manufacture and commercialize evenamide in South Korea Myung In Pharm to contribute 10% of patients to Newron’s pivotal Phase III trial for evenamide, and share global development costs Newron will receive upfront payment, development and [ … ]